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Tuberculosis controlAbstract World Health Organization (WHO) control policy for tuberculosis (TB)
includes Bacillus Calmette-Gue´rin (BCG) vaccine at birth, case detection, and
treatment of cases with directly observed therapy short-course (DOTS). This policy
has been applied through the Ministry of Health and Population in Egypt for more
than 30 years. The controversies about the efficacy of the BCG vaccination against
TB in adults initiate some suggestions for its discontinuation from compulsory
vaccinations in countries with low incidence of TB. The present work aimed to study
the trend of applying the WHO control policy for TB in Egypt among the Egyptian
population throughout the last 20 years (1992–2011). The documented database
of the country, bibliographic review on MEDLINE, published studies and reports,
WHO and EMRO databases that covered the period from 1992 to 2011 were used
in this study. The incidence rate of all forms of TB (pulmonary and extrapulmonary)
dropped by 50% from 34 cases to 17 cases per 100,000 population, as well as the
prevalence rate declined by 60.6% from 71 cases per 100,000 population throughout
the last 20 years. Case detection and treatment success rates have increased
throughout the studied period while it flat-lined over the past 6 years which
may need attention. The results of this study introduce an evidence-based
recommendation for continuation of the WHO TB control policy in Egypt towards
elimination of the disease.
ª 2014 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/1. Introduction
Tuberculosis (TB) remains a major global health
problem. It ranks as the second leading cause ofdeath from an infectious disease worldwide, after
the human immunodeficiency virus (HIV). The latest
estimates by the World Health Organization (WHO)
reported that there were 9 million new cases in
2011 and 1.4 million TB deaths [1]. Moreover, it is
one of the top 10 causes of global mortality and
196 A. Saad-Hussein, A.M. Mohammedaffects low-income countries in particular. About
half a million children (0–14 years old) are ill with
TB, and 64,000 children died from the disease in
2011 [2]. In Egypt, TB is considered the third
most important public health problem after
schistosomiasis and hepatitis C [3,23]. The objec-
tives of WHO in TB control policy are to reduce mor-
tality, prevalence and incidence of TB. The basis of
this policy for TB control depends on early case
detection, proper treatment of cases with directly
observed therapy short-course (DOTS), in addition
to the compulsory BCG vaccination [4,5]. In 1996,
the National TB program of Egypt took action to
tackle low adherence of patients to TB treatment
and began implementation of the DOTS program
[6]. This action improved the average rate of
defaulting in Egypt in 2008 to 4% [7]. Clinical trials
have demonstrated conflicting results regarding
BCG vaccine efficacy. Meta-analytic reviews have
estimated the vaccine efficacy in preventing any
type of TB at approximately 51% [8]. The protective
effect of BCG vaccine against disseminated TB in
the newborn is estimated to be 78%. Although gen-
erally the duration of the BCG vaccine protection is
not well-established, one follow-up study demon-
strated a protective effect for up to 60 years [9].
The International Union against Tuberculosis and
Lung Disease suggested that routine BCG vaccina-
tion should be discontinued when the notification
rate of pulmonary TB reaches less than 5 per
100,000 population per year [10]. One of the targets
of the United Nations millennium development
goals, by 2015, is to halt the mortality and morbid-
ity indicators of TB, improving the case detection
rate to reach 70% and treatment success rate to
reach 85%. The present study aimed to present
the trend of the application of the WHO TB control
policy in Egypt throughout the last 20 years (1992–
2011).
2. Methodology
2.1. Collection of data
1. Data about immunization coverage rates of
the compulsory BCG vaccination for Egyptian
children, under 5 years old mortality rates
due to TB, morbidity and mortality rates of
TB of all forms in all age groups, case detec-
tion and treatment success rates of TB were
used in the present study.
2. Sources of data: Bibliographic review on MEDLINE,
published studies and reports, and WHO and EMRO
online databases that covered the period from
1992 to 2011 [11,12].3. The data were revised and filtered according to
documentation; all non-documented data were
excluded from the final statistical analysis.
2.2. Statistical analysis of the collected data
Statistical models are used to identify the time
trend of the above-mentioned predictor variables
of TB. Pearson correlation coefficient and linear
regression models were used to study the relation-
ships between the predictor variables (e.g., the
BCG immunization coverage, case detection rate
and treatment success rate) and the outcome of
interest (e.g., morbidity and mortality rates of
TB) using SPSS version 18.0. The significance level
was considered at P-value <0.05.3. Results
Statistical analysis of the collected data revealed
that there was a high statistically significant in-
crease in the coverage rate of compulsory BCG vac-
cination during the last 20 years (r = 0.7,
P = 0.001). This increase was in two steps from
92% to 95% between the years 1992 and 1993, and
the second step was between the years 1996 and
1997 from 95% to 98% with few exceptions as shown
in Fig. 1. In 1998 and in 2006, there was an increase
in the coverage rate reaching 99%.
The TB case detection and treatment success
rates were increasing throughout the duration
(1992–2011) with a fluctuating trend from progres-
sion to regression and so on with a plateau over the
past 5 years (Figs. 2 and 3, respectively).
Moreover, severe declines were observed in
the trend of the TB mortality rate per 100,000
population as well as in the under 5 years old
TB mortality rate per 1000 live births during the
period 1992–2011 (Figs. 4 and 5, respectively),
as there were significant inverse correlations
between the time in years and the rates of TB
mortality and under 5 years old mortality
(r = 0.85, P < 0.0001 and r = 0.99, P < 0.0001,
respectively).
Statistically significant inverse correlations
were also detected between the time in years
and the TB morbidity rates per 100,000 population
(incidence and prevalence rates; r = 0.99,
P < 0.0001, and r = 0.94, P < 0.0001, respectively)
(Fig. 6).
There were significant inverse correlations be-
tween the BCG vaccination coverage rate and the
rates of TB morbidity and mortality, and under
5 years old mortality (Table 1). There were also sig-
nificant inverse correlations between the rates of
Fig. 1 Trend of BCG immunization coverage in Egypt during the period 1992–2011.
Fig. 2 The trend of TB case detection rate in Egypt during the period 1992–2011.
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the rates of TB morbidity and mortality, and under
5 years old mortality.
4. Discussion
The WHO declared TB a global public health emer-
gency in 1993. Starting in the mid-1990s, efforts to
improve TB care and control intensified at national
and international levels. WHO developed the DOTS
strategy, diagnosis using sputum smear micros-
copy, a regular supply of first-line anti-TB drugs,
short-course chemotherapy and a standard system
for recording and reporting the number of casesdetected by national TB control programs (NTPs)
and the outcomes of treatment [1]. The WHO also
recommends neonatal BCG vaccination in countries
with a high prevalence of TB as one of the preven-
tive measures of TB control [2]. It is used in over
150 countries and is mainly given in the neonatal
period [13]. In Egypt, BCG vaccination became
compulsory in all governorates of Egypt since
1974 [14].
In the current work, the trend of application of
the WHO control strategy for TB in Egypt in the
form of the rates of case detection, treatment suc-
cess, and mandatory coverage of BCG vaccine, and
the efficacy of this strategy on the burden of TB
Fig. 3 The trend of treatment success rate in Egypt during the period 1992–2011.
Fig. 4 Trend of mortality rate of TB in Egypt during the period 1992–2011.
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were studied using statistical analysis of the docu-
mented data.
Marked improvement was noticed in the per-
centage of newly notified TB cases (case detection
rate), including relapses. Moreover, the improve-
ment was extended to reach the percentage of
newly registered smear-positive (infectious) casesthat were cured or in which a full course of treat-
ment was completed (DOTS treatment success
rate).
It was observed that the TB case detection rate
has improved from 45% to 65% while the treatment
success rate has improved from 52% to 86% with
marked fluctuation between increase and decrease
and so on throughout the studied period (1992–
Table 1 Correlations between BCG vaccination coverage rate and the rates of TB (case detection, treatment success,
morbidity and mortality, and under 5 years old mortality rates) in the period 1992–2011.
Incidence rate Prevalence rate Mortality rate Under 5 years old
mortality rate
R P-value R P-value r P-value R P-value
BCG coverage rate 0.74 <0.0001 0.86 <0.0001 0.86 <0.0001 0.77 <0.0001
Case detection rate (%) 0.57 0.008 0.72 <0.0001 0.84 <0.0001 0.63 0.003
Treatment success rate (%) 0.7 0.001 0.82 <0.0001 0.75 <0.0001 0.75 0.001
Fig. 5 Trend of under 5 mortality rate of TB among the Egyptian children during the period 1992–2011.
Fig. 6 Trend of TB morbidity rates in Egypt during the period 1992–2011.
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detection rate were observed in 1997 and 2005,
where it reached 75% and 73%, respectively. Simi-
larly, the most prominent peak of increase in the
DOTS treatment success rate was in the years
2007 and 2008 where it reached 89% (Figs. 2 and
3). It is observed that the treatment success rate
has declined slowly after the second peak to reach
86%, which is still above the global target (85%).
It was also noticed that in the past six years, the
case detection rates have become flat (leveled off)
at 65% (Fig. 2), which is an alarming sign because it
is less than the global target of 70%. However, the
two statements may need more attention from the
Egyptian national TB control program.
Strong inverse correlation was observed be-
tween TB case detection rates, treatment success
rates and the rates of TB under 5 years mortality,
and TB mortality and morbidity (incidence and
prevalence rates) (Table 1). Egypt was classified
as one of the 36 worldwide countries having
achieved the global targets in both case detection
and treatment success under DOTS [11]. However,
WHO has identified five priority actions for further
improvement of case detection and treatment suc-
cess rates, as well as for more progression towards
2015 global targets [24]. These five actions include:
better efforts to reach the missed cases through
instituting mandatory notification and reporting
systems in private and non-governmental health
facilities. Another priority is addressing Multiple
Drug Resistant (MDR-TB) cases through proper diag-
nosis and better supply of the effective treatment
[24].
The currently recommended WHO approach to
TB care and control is the Stop TB Strategy,
launched in 2006. This Strategy was linked to new
global targets for reductions in TB cases and deaths
that were set for 2015 as part of the Millennium
Development Goals (MDGs) and by the Stop TB
Partnership. The targets are that TB incidence
should be falling by 2015, and that prevalence
and death rates should be halved compared with
their levels in 1990 [1]. In the present study, statis-
tically significant declines in the trend of TB mor-
bidity (incidence and prevalence) and mortality
rates with time were detected during the period
1992–2011. The incidence rate of all forms of TB
(pulmonary and extrapulmonary) dropped by 50%
from 34 cases per 100,000 population in the year
1992 to 17 cases per 100,000 population in the year
2011. The TB prevalence rate declined also
throughout the last 20 years by 60.6% from 71 cases
per 100,000 population in 1992 to 28 cases per
100,000 population in 2011 (Figs. 4 and 6). Theseresults indicate that TB is regressing in Egypt, thus
it was ranked by WHO as a country with intermedi-
ate incidence of TB in the Eastern Mediterranean
Region (EMR).
On the other hand, the protective efficacy of
BCG remains controversial, varying from 0% to
80% in different populations and geographic regions
[15]. However, BCG currently remains the only vac-
cine available, particularly for severe forms of TB
in children. Various explanations for the variability
of BCG efficacy in the different trials and popula-
tions are still under study, including latitude varia-
tion, differences in vaccine strain, vaccine dose,
virulence of Mycobacterium tuberculosis strains,
genetic make-up of vaccinees, nutritional status
of vaccinees and methodological differences
[9,16]. In this work, the compulsory vaccination
coverage rate of BCG was significantly increased
during the last 20 years (1992–2011) among chil-
dren in Egypt, with two peaks of increase in the
years 1998 and 2006, where it reached 99% (Fig. 1).
The meta-analysis of data from 14 prospective
trials and 12 case-control studies of BCG efficacy
indicates that vaccination with BCG significantly
reduces the risk of TB by an average of 50%. This
level of protection persists across a number of sub-
groups of the studies defined by age at vaccination
and study design. Age at vaccination was not a sig-
nificant predictor of BCG efficacy. Vaccination with
BCG was significantly associated with reduction in
pulmonary and extrapulmonary TB [17].
In the present study, the coverage rate of com-
pulsory BCG vaccination revealed a strong statisti-
cally significant inverse correlation with both TB
morbidity indicators (incidence and prevalence
rates) (Table 1). It was observed that the decline
in the prevalence of the disease showed a rapid de-
cline rate, from 71 to 43 cases per 100,000 popula-
tion (34.4%) within the period 1992–1998, which is
synchronous with the first peak of increase in BCG
vaccination coverage rate at the year 1998, where
it reached 99% coverage rate. After this first peak,
the prevalence rate was decreased at a slower rate
(Fig. 6).
The WHO global TB situation report mentioned
that more than 50,000 deaths in children world-
wide aged 0–4 years can be prevented by increas-
ing the BCG coverage rate [5]. In the present
study, a strong statistically significant inverse cor-
relation was detected between the BCG vaccina-
tion coverage rate and the under-5 years old
mortality rate (Table 1). In addition, a statistically
significant decline was observed in the trend of un-
der-5 years mortality rate during the period (1992–
2011) by 72.3% from 76 to 21 deaths per 1000 live
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51 (32.9%) deaths per 1000 live births within the
first 7 years of the studied period (1992–1998),
which is synchronous with the first peak of increase
in the BCG vaccination coverage rate at the year
1998 where it reached 99%. After this first peak,
the under-5 years mortality rate was decreased
by a slower rate throughout the resting 13 years
of the studied period (1999–2011) where it de-
clined from 48 to 21 deaths per 1000 live births
(Fig. 5). This finding may be in agreement with
Garly et al. [18] and Roth et al. [19], where they
found that the BCG vaccine enhances and promotes
a T-helper-1 immune response and consequently it
might reduce the mortality due to other causes of
mortalities in this age in addition to the mortalities
due to severe forms of TB as well.
Trunz et al. [20] found that the 100 million doses
of BCG vaccine given to children every year glob-
ally prevent about 40,000 cases of tuberculous
meningitis and miliary TB before these children
reach their fifth birthdays, or roughly one case pre-
vented for every 2500 inoculations.
Randomized controlled trials and case-control
studies have shown variable efficacy of BCG against
pulmonary TB in adults [20–22]. In the present
work, the mortality rate due to TB in all age groups
dropped in Egypt by 77.1% from 3.5 to 0.8 deaths
per 100,000 population between 1992 and 2011
(Fig. 4), and the TB mortality rate was inversely
correlated with the compulsory BCG coverage rate
(Table 1).5. Conclusion
Although TB control is a multidimensional prob-
lem, TB in Egypt is regressing in both mortality
and morbidity indicators, despite the observed
fluctuation in TB case detection rate that
reached 65% in 2011 with a marked plateau
throughout the past 6 years, which is less than
the global target. WHO has succeeded to achieve
a sustained treatment success rate exceeding the
global target (85%) since 2006 until now; further-
more, it succeeded to maintain a higher level of
the BCG vaccination coverage rate (98%) since
1997 until now. Application of the WHO control
strategy for TB in Egypt is considered comple-
mentary to each other towards elimination of
the disease. Even the compulsory BCG vaccina-
tion at birth may play a role in decreasing the
burden of disease either through its non-specific
effect on immune system and/or through preven-
tion of progression of infection to disease. More
attention is needed for improvement in casedetection to reach its global target and to pre-
vent further regression in the treatment success
rate.Conflict of interest
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